Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
HMGB1High Mobility Group Box 1
References in periodicals archive ?
Further studies elucidate that some ingredient pertain to YTE is effective to antagonize HMGB1 activity, collagen production, and attenuate myocardial fibrosis and hepatic fibrosis by disrupting TGF-[beta]1 signaling (Huang et al.
Research over the past few years has demonstrated that two natural ingredients can directly control HMGB1, switching off the massive cytokine flow that generates age-related inflammation and leads to disease and premature death.
37) Studies have shown that the HMGB1 plasma level, one of the main RAGE ligands, is increased in the circulation of SLE, leading to the binding and consumption of sRAGE during the inflammatory process.
Sama, MD, at the Feinstein Institute found that extract from mung bean (Vigna radiata), a bean native to India and commonly used in Chinese food and traditional medicine, reduced the release of HMGB1, thereby increasing survival rates in mice from 29.
With this acquisition, the company has gained a dominant position in the field of HMGB1 since its patent portfolio covers the use of HMGB1 antagonists (e.
Research showed wounded mice with skin grafts produced high levels of HMGB1.
Recent studies have identified the endogenous nuclear protein HMGB1 as a master regulator of innate immunity and as a key player in the pathogenesis of systemic lupus erythematosus (13).
Twenty-four hours later, they gave half the animals antibodies against HMGB1, and the other mice received unrelated antibodies.
Critical Therapeutics has two preclinical programs, alpha-7 and HMGB1, and two clinical-stage programs, zileuton injection and R(+) zileuton, in its product pipeline.
Our recent discovery of HMGB1 as a late mediator of lethal sepsis has prompted investigation for development of new experimental therapeutics.
The researchers also found that patients exposed to asbestos have elevated levels of HMGB1 in their serum.
The Company continues its collaboration with MedImmune for the development of human monoclonal antibodies targeted at the cytokine HMGB1.